Phase I Dose-Escalation Study of SCB01A,a Microtubule Inhibitor with Vascular Disrupting Activity,in Patients with Advanced Solid Tumors

Lessons Learned

• SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
• This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
• SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.

BackgroundSCB01A, a novel microtubule inhibitor, has vascular disrupting activity.MethodsIn this phase I dose‐escalation and extension study, patients with advanced solid tumors were administered intravenous SCB01A infusions for 3 hours once every 21 days. Rapid titration and a 3 + 3 design escalated the dose from 2 mg/m² to the maximum tolerated dose (MTD) based on dose‐limiting toxicity (DLT). SCB01A‐induced cellular neurotoxicity was evaluated in dorsal root ganglion cells. The primary endpoint was MTD. Safety, pharmacokinetics (PK), and tumor response were secondary endpoints.ResultsTreatment‐related adverse events included anemia, nausea, vomiting, fatigue, fever, and peripheral sensorimotor neuropathy. DLTs included grade 4 elevated creatine phosphokinase (CPK) in the 4 mg/m² cohort; grade 3 gastric hemorrhage in the 6.5 mg/m² cohort; grade 2 thromboembolic event in the 24 mg/m² cohort; and grade 3 peripheral sensorimotor neuropathy, grade 3 elevated aspartate aminotransferase, and grade 3 hypertension in the 32 mg/m² cohort. The MTD was 24 mg/m², and average half‐life was ~2.5 hours. The area under the curve‐dose response relationship was linear. Nineteen subjects were stable after two cycles. The longest treatment lasted 24 cycles. SCB01A‐induced neurotoxicity was reversible in vitro.ConclusionThe MTD of SCB01A was 24 mg/m² every 21 days; it is safe and tolerable in patients with solid tumors.     

补肾排毒合剂治疗慢性肾衰竭营养不良60例临床观察

目的:观察补肾排毒合剂治疗慢性肾衰竭营养不良的疗效.方法:90例慢性肾衰竭营养不良患者随机分为治疗组60例和对照组30例,并设健康对照组30例.治疗组和对照组在综合治疗的基础上,治疗组加用补肾排毒合剂,对照组加用爱西特和百令胶囊.比较两组肾功能、营养状态和血浆瘦素、神经肽Y的变化.结果:治疗组治疗后BUN、Scr明显降低,与治疗前及对照组相比均有统计学差异(P<0.05).治疗组营养状态好转,与治疗前及对照组相比均有统计学差异(P<0.05).两组慢性肾衰竭营养不良患者治疗前Leptin、NPY水平均高于健康组(P<0.05),治疗后治疗组Leptin、NPY较治疗前下降,有统计学意义(P<0.05),但与对照组相比无统计学差异(P＞0.05).结论:补肾排毒合剂治疗慢性肾衰竭营养不良疗效明显,可降低BUN、Scr,改善营养不良状态.     

Acute Immobilization Stress and Intraventricular Injection of CRF Suppress Naloxone-Induced LH Release in Ovariectomized Estrogen-Primed Rats

The present study was undertaken to evaluate the role and possible interaction of the endogenous opioid peptide (EOP) and corticotropin-releasing factor (CRF) in the acute stress-induced suppression of gonadotropin secretion in ovariectomized estrogen-primed rats. An intravenous (i.v.) injection of naloxone (10 or 20  mg/kg), an EOP antagonist, significantly elevated serum luteinizing hormone (LH) levels within 10  min in non-stressed animals. The naloxone-induced LH release was completely eliminated when tested 30  min after the onset of acute immobilization. In a subsequent study, it was found that suppression of the naloxone-induced LH release occurred as early as 5  min after the stress onset, and was still evident 60  min after the end of a 30-min period of immobilization. The effect of naloxone was restored 3  h after liberation of the animal from the 30-min immobilization. An intraventricular (i.c.v.) injection of CRF (1 or 5  μg) also significantly suppressed, in a dose-related manner, the effect of a subsequent i.v. injection of naloxone. However, an i.c.v. injection of α -helical CRF(9-41) (25 or 50  μg), a CRF antagonist, prior to immobilization, could not interfere with the suppressive effect of stress on naloxone-induced LH release. These results suggest that both acute immobilization stress and CRF can inhibit the LH secretory activity without mediation by EOP neurons. However, the stress-related suppression may involve non-CRF mechanism(s).     

慢性肾衰竭血液透析患者心理卫生状况调研

目的 :了解慢性肾衰竭血透患者的心理卫生状况。方法 :用SCL - 90量表对 6 5名慢性血透患者进行测量 ,测量结果与国内正常人群进行比较 ,并对该人群心理问题发生率作出估计。结果 :血透患者的SCL - 90总分(14 9.4 6± 5 0 .88)分 ,总均分 (1.6 6± 0 .5 7)分 ,阳性项目数 (34.0 3± 2 3.0 7)个 ,阳性均分 (2 .4 6± 0 .84 )分 ,在本组人群中心理障碍的检出率为 15 .38% ,男性与女性之间无差异 (χ2 =0 .0 0 4 ,P >0 .0 5 ) ,血透患者组的SCL - 90因子分中躯体化、抑郁、焦虑、精神病性、强迫、敌意和恐怖因子与国内正常人群有差异 (P <0 .0 5～ 0 .0 0 1)。结论 :慢性肾衰竭血透患者的心理卫生状况明显低于国内正常人群 ,其中 15 .38%的患者存在心理障碍 ,主要以躯体化、抑郁、焦虑、精神病性为主 ,对躯体疾病的治疗中应兼顾心理问题的诊断与治疗     

基于非标准协议无线通信的个人健康监护系统设计

基于非标准协议的短距离无线通信，具有成本低、易开发、低功耗的优点，非常适用于小范围内的数据传输。提出一种基于非标准无线通信芯片nRF24L01的个人健康监护系统设计方案，并将其与现有的、基于标准协议无线通信的个人健康监护系统进行比较。结果表明：基于非标准协议无线通信的个人健康监护系统具有效率高、功耗低、通信性能好的特点。     

Evaluation of the impedance tonometers TGDc-01 and iCare according to the international ocular tonometer standards ISO 8612

BACKGROUND: Two new tonometers have been introduced that are based on the impedance principle. Both the TGDc-01 (transpalpebral measurement) and the iCare (corneal measurement) do not require corneal anaesthesia. The present work presents an evaluation of both devices. METHODS: Comparative measurements using one of the new tonometers and applanation tonometry were performed by one investigator according to the international standard for ocular tonometer (ISO 8612). Measurements were performed on 445 eyes without corneal pathology from 243 patients. Six measurements were performed for iCare and 3 for TGDc, immediately followed by 3 applanation tonometry measurements. RESULTS: The correlation coefficient with respect to applanation tonometry was 0.81 for TGDc and 0.95 for iCare. TGDc-01 measurements showed an average deviation of 3.1 +/- 2.6 mmHg to those of Perkins applanation tonometry. The maximum difference was 28.7 mmHg below and 9.8 mmHg above the results of applanation tonometry. iCare showed an average deviation of 2.5 +/- 1.1 mmHg to Goldmann tonometry. The maximum difference was 14.5 mmHg below and 9.8 mmHg above. CONCLUSIONS: The results of both new tonometers showed a good correlation with the reference applanation tonometric methods, but the strict requirements of ISO 8612 are not fulfilled by either tonometer at present. Additionally, transpalpebral measurements with the TGDc-01 showed unacceptably high variability.     

Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells

Summary Impairment of skeletal muscle function is the common feature of distinct clinical forms of glycogenosis type II. In the present study, muscle cultures from different patients were used to investigate the cause of clinical heterogeneity and the feasibility of enzyme replacement therapy. The activity of acid -glucosidase appears to be the primary factor in determining the extent of lysosomal glycogen storage in muscle, and thereby the clinical severity of the disease. Neutral -glucosidases do not seem influencial. Correction of the enzymatic defect was achieved in skeletal muscle cultures from patients by administration of a high-uptake form of acid -glucosidase, purified from human urine. The enzyme reaches the lysosomes, including the glycogen storage vacuoles, and the lysosomal glycogen content is reduced to control level. In normal muscle cells 20% of the total cellular glycogen pool is segregated in lysosomal compartments. This percentage is higher than in fibroblasts, which may partly explain why muscles are more prone to store glycogen. The relevance of this study for enzyme therapy is discussed.     

Glucose preferences in wild and domestic guinea pigs

Male wild (Cavia aperea) and domestic (C. porcellus) guinea pigs were tested in two-bottle choice tests for preferences between glucose solutions of different concentrations and de-ionized water. Wild males showed significant preferences for concentrations between 0.025 and 0.4 M glucose while domestic males preferred only the 0.2 M glucose solution to de-ionized water. C. aperea males also consumed significantly greater volumes of liquid per kg body $\text{wt.}{}^{\mathrm{<mtext>3</mtext><mtext>4</mtext>}}$ during the glucose tests than did the C. porcellus males. These comparative results contrast sharply with those obtained by other authors with wild and domestic Norway rats.     

Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability

1. Download : Download high-res image (382KB)
2. Download : Download full-size image